Published in Law and Health Weekly, March 20th, 2010
the Netherlands Vaccine Institute announce the launch of their joint AmpVacs project aiming at the development of a broadly protective synthetic influenza A vaccine component that in combination with classical antibody-stimulating vaccines will induce protection against future influenza A threats.
The preclinical research phase of the project is funded by the Joint Call initiative of the three Dutch Public Private Partnerships, the BioMedical Materials (BMM) program, the Centre for Translational Molecular Medicine
(CTMM) and Top Institute Pharma (TI Pharma),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly